Biotech M&A slows sharply in Q3 as deal activity cools
read at Endpoints ↗DealNegative
The third quarter saw a noticeable slowdown in biotech mergers and acquisitions after a busy first half of the year.
Large upfront licensing agreements were fewer, and venture capital firms reduced the pace of new investments, reflecting broader market caution.
Analysts note that the cooling of deal activity could pressure biotech financing and may lead companies to focus on internal development rather than external partnerships.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Biotech takes a hit as dealmakers take a knee in Q3”
read at Endpoints ↗69 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that